UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:February 26, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:February 26, 2024Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:August 14, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:June 6, 2023Completed
Condition(s):Relapsed and Refractory Multiple MyelomaLast Updated:December 17, 2020Completed
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:November 15, 2022Approved for marketing
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 18, 2024Recruiting
Condition(s):Refractory Multiple Myeloma; Relapse Multiple MyelomaLast Updated:August 19, 2020Withdrawn
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 14, 2023Active, not recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 8, 2024Recruiting
Condition(s):Relapsed and/or Refractory Multiple MyelomaLast Updated:April 18, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.